Skip to main contentSkip to main content
You have permission to edit this article.
Edit

Adolescent Sleep Patterns Tied to Later Multiple Sclerosis Risk

  • Updated

WEDNESDAY, Jan. 25, 2023 (HealthDay News) -- Insufficient sleep and low sleep quality during adolescence may increase the risk for subsequently developing multiple sclerosis, according to a study published online Jan. 23 in the Journal of Neurology, Neurosurgery & Psychiatry.

Torbjörn Åkerstedt, Ph.D., from Stockholm University, and colleagues assessed the impact of sleep duration, circadian disruption, and sleep quality on multiple sclerosis risk. The analysis included 2,075 multiple sclerosis cases and 3,164 controls.

The researchers found that compared with sleeping seven to nine hours a night during adolescence, short sleep duration (less than seven hours a night) was associated with an increased risk for developing multiple sclerosis (odds ratio, 1.4). Self-reported low sleep quality during adolescence also increased the risk for subsequently developing multiple sclerosis (odds ratio, 1.5). However, phase shift did not significantly influence multiple sclerosis risk. Findings remained similar when the analysis excluded those who worked shifts.

"Insufficient sleep and low sleep quality during adolescence dose-dependently increased the risk of multiple sclerosis. A change in sleep timing between work/school days and weekends/free days did not influence the risk of the disease," the authors write. "Educational interventions addressed to adolescents and their parents regarding the negative health consequences of insufficient sleep are of importance."

Abstract/Full Text

Originally published on consumer.healthday.com, part of the TownNews Content Exchange.


Subscribe to stay connected to Tucson. A subscription helps you access more of the local stories that keep you connected to the community.

* I understand and agree that registration on or use of this site constitutes agreement to its user agreement and privacy policy.

Related to this story

Most Popular

FRIDAY, Jan. 20, 2023 (HealthDay News) -- Among an average-risk population, follow-up colonoscopy (FU-CY) rates are low after a positive noninvasive stool-based screening test (SBT) for colorectal cancer, according to a study published online Jan. 18 in JAMA Network Open.

Scientists say delivering gene therapy directly to the brain holds great promise. The first brain-delivered gene therapy on the market was recently approved in Europe and the U.K. for a rare genetic disorder called AADC deficiency. It causes developmental delays and movement disorders in kids. New Jersey drugmaker PTC Therapeutics plans to seek approval for the treatment in the U.S. this year. Meanwhile, about 30 studies in the U.S. are testing gene therapy directly to the brain for other disorders, including Alzheimer’s and Parkinson’s. Challenges remain, especially with diseases caused by more than a single gene. But scientists say the evidence supporting this approach is mounting.

Listen now and subscribe: Apple Podcasts | Google Podcasts | Spotify | Stitcher | RSS Feed | Omny Studio

Get up-to-the-minute news sent straight to your device.

Topics

News Alerts

Breaking News